Cargando…
Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study
PURPOSE: To compare the efficacy and safety of conbercept and ranibizumab when administered according to a treat-and-extend (TREX) protocol for the treatment of neovascular age-related macular degeneration (AMD) in China. PATIENTS AND METHODS: Between May 2014 and May 2015, 180 patients were treated...
Autores principales: | Cui, J, Sun, D, Lu, H, Dai, R, Xing, L, Dong, H, Wang, L, Wei, D, Jiang, B, Jiao, Y, Jablonski, M M, Charles, S, Gu, W, Chen, H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805597/ https://www.ncbi.nlm.nih.gov/pubmed/28937147 http://dx.doi.org/10.1038/eye.2017.187 |
Ejemplares similares
-
Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
por: Wang, Luping, et al.
Publicado: (2018) -
Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration
por: Wang, Zongyi, et al.
Publicado: (2020) -
Profile of conbercept in the treatment of neovascular age-related macular degeneration
por: Lu, Xinmin, et al.
Publicado: (2015) -
Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006) -
Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)